Granada, 7 March 2016. Neuron Bio has been designated by Merck Millipore as reference laboratory for the Milliplex® immunoassays technology focused on the identification of biomarkers.
Neuron Bio uses the Merck Millipore Milliplex® technology since 2011, employed by the company in the creation of AlzTest®, its test to aid in the diagnosis of Alzheimer’s disease. Pharmaceuticals companies, hospitals and research groups have signed with Neuron Bio R&D service contracts using this technology for the identification of biomarkers aimed at new therapeutic indications and research projects.
The agreement with Merck Millipore together with recent progress in the diagnostic area reinforces the main lines of the company new business plan. It will allow Neuron Bio to increase the provision of R&D services in the area of biomarkers and the development of internal and for third parties diagnostic tools.
Neuron Bio will perform tests for its clients using Milliplex® technology that is property of Merck Millipore, which will strengthen commercial lines of both companies, thus consolidating the close relationship between both companies that least over five years.
The Milliplex® technology enables to determine in a quick, simple and reproducible manner levels of biomarkers panels through analysis in tissues and fluids of different laboratory animals and human samples.
In words of Javier Burgos, the CEO of Neuron Bio, “To become reference laboratory of Merck Millipore is the result of work carried out during the last five years as reference company in the use of this state-of-the-art technology in the field of biomarkers identification. This agreement allows us to strengthen two areas that we consider critical in coming years; diagnostic of human disease and enhancement of R&D services for third parties.”